Researchers from DZNE have identified a protein in the blood that may indicate the degradation of neural connections years before the onset of dementia symptoms.
A European research consortium led by DZNE will be investigating the neurodegenerative disease “Spinocerebellar Ataxia Type 3” (SCA3) in collaboration with the French pharmaceutical company Servier Laboratories.
In individuals with a genetic predisposition to Alzheimer’s disease, the immune cells of the brain – the “microglia” – start exerting a protective effect up to two decades before the first symptoms appear.
Welcome to our website, here you can inform yourself basically cookie-free.
We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.
